Comprehensive Review of the Utility of Dynamic Contrast-Enhanced MRI for the Diagnosis and Treatment Assessment of Spinal Benign and Malignant Osseous Disease

References

1. 1.↵
   1. Maccauro G,
   2. Spinelli MS,
   3. Mauro S, et al

   . Physiopathology of spine metastasis. Int J Surg Oncol 2011;2011:107969 doi:10.1155/2011/107969 pmid:22312491

   CrossRefPubMed
2. 2.↵
   1. Gerszten PC,
   2. Mendel E,
   3. Yamada Y

   . Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) 2009;34:S78–92 doi:10.1097/BRS.0b013e3181b8b6f5 pmid:19829280

   CrossRefPubMed
3. 3.↵
   1. Chao ST,
   2. Koyfman SA,
   3. Woody N, et al

   . Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. Int J Radiat Oncol Biol Phys 2012;82:1738–43 doi:10.1016/j.ijrobp.2011.02.019 pmid:21489717

   CrossRefPubMed
4. 4.↵
   1. Harel R,
   2. Angelov L

   . Spine metastases: current treatments and future directions. Eur J Cancer 2010;46:2696–707 doi:10.1016/j.ejca.2010.04.025 pmid:20627705

   CrossRefPubMed
5. 5.↵
   1. Barzilai O,
   2. Laufer I,
   3. Yamada Y, et al

   . Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanicals stability, and systemic disease. J Clin Oncol 2017;35:2419–27 doi:10.1200/JCO.2017.72.7362 pmid:28640703

   CrossRefPubMed
6. 6.↵
   1. Shih TT,
   2. Huang KM,
   3. Li YW

   . Solitary vertebral collapse: distinction between benign and malignant causes using MR patterns. J Magn Reson Imaging 1999;9:635–42 doi:10.1002/(SICI)1522-2586(199905)9:5<635::AID-JMRI4>3.0.CO;2-E

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Larsen VA,
   2. Simonsen HJ,
   3. Law I, et al

   . Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology 2013;55:361–69 doi:10.1007/s00234-012-1127-4 pmid:23262559

   CrossRefPubMed
8. 8.↵
   1. O'Connor JPB,
   2. Jackson A,
   3. Parker GJM, et al

   . DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189–95 doi:10.1038/sj.bjc.6603515 pmid:17211479

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Ramakrishna R,
   2. Magge RS,
   3. Baaj AA, et al.

   1. Karimi S,
   2. Cho NS,
   3. Peck KK, et al

   . The role of advanced imaging in spinal metastases. In: Ramakrishna R, Magge RS, Baaj AA, et al., eds. Central Nervous System Metastases: Diagnosis and Treatment. Cham, Switzerland: Springer-Verlag International Publishing 2020:523–34
10. 10.↵
    1. Gilbert FJ,
    2. Ahearn TS

    . Dynamic contrast-enhanced MRI in cancer. Imag Med 2009;1:173–86 doi:10.2217/iim.09.17

    CrossRef
11. 11.↵
    1. Vaupel P,
    2. Kallinowski F,
    3. Okunieff P

    . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449–65

    Abstract/FREE Full Text
12. 12.↵
    1. Nielsen T,
    2. Wittenborn T,
    3. Horsman MR

    . Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in preclinical studies of antivascular treatments. Pharmaceutics 2012;4:563–89 doi:10.3390/pharmaceutics4040563 pmid:24300371

    CrossRefPubMed
13. 13.↵
    1. Choyke PL,
    2. Dwyer AJ,
    3. Knopp MV

    . Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17:509–20 doi:10.1002/jmri.10304 pmid:12720260

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Traill Z,
    2. Richards MA,
    3. Moore NR

    . Magnetic resonance imaging of metastatic bone disease. Clin Orthop Relat Res 1995;76–88
15. 15.↵
    1. Jackson A,
    2. Buckley DL,
    3. Parker GJM

    1. Parker GJM,
    2. Buckley DL

    . Tracer kinetic modelling for T1-weighted DCE-MRI. In: Jackson A, Buckley DL, Parker GJM, eds. Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology. Berlin, Heidelberg: Springer-Verlag 2005:81–92
16. 16.↵
    1. De Naeyer D,
    2. Verhulst J,
    3. Ceelen W, et al

    . Flip angle optimization for dynamic contrast-enhanced MRI-studies with spoiled gradient echo pulse sequences. Phys Med Biol 2011;56:5373–95 doi:10.1088/0031-9155/56/16/019 pmid:21804179

    CrossRefPubMed
17. 17.↵
    1. Saranathan M,
    2. Rettmann DW,
    3. Hargreaves BA, et al

    . DIfferential Subsampling with Cartesian Ordering (DISCO): a high spatio-temporal resolution Dixon imaging sequence for multiphasic contrast enhanced abdominal imaging. J Magn Reson Imaging 2012;35:1484–92 doi:10.1002/jmri.23602 pmid:22334505

    CrossRefPubMed
18. 18.↵
    1. Chen W-T,
    2. Shih TT-F,
    3. Chen R-C, et al

    . Blood perfusion of vertebral lesions evaluated with gadolinium-enhanced dynamic MRI: in comparison with compression fracture and metastasis. J Magn Reson Imaging 2002;15:308–14 doi:10.1002/jmri.10063 pmid:11891976

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Verma S,
    2. Turkbey B,
    3. Muradyan N, et al

    . Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol 2012;198:1277–88 doi:10.2214/AJR.12.8510 pmid:22623539

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Jackson A,
    2. Li K-L,
    3. Zhu X

    . Semi-quantitative parameter analysis of DCE-MRI revisited: Monte-Carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis. PLoS One 2014;9:e90300 doi:10.1371/journal.pone.0090300 pmid:24594707

    CrossRefPubMed
21. 21.↵
    1. Tofts PS,
    2. Brix G,
    3. Buckley DL, et al

    . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Dehkordi ANV,
    2. Kamali-Asl A,
    3. Wen N, et al

    . DCE-MRI prediction of survival time for patients with glioblastoma multiforme: using an adaptive neuro-fuzzy-based model and nested model selection technique. NMR Biomed 2017;30:e3739doi:10.1002/nbm.3739

    CrossRef
23. 23.↵
    1. O'Connor JPB,
    2. Tofts PS,
    3. Miles KA, et al

    . Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiology 2011;84 Spec No 2:S112–20 doi:10.1259/bjr/55166688 pmid:22433822

    CrossRefPubMed
24. 24.↵
    1. Gordon Y,
    2. Partovi S,
    3. Müller-Eschner M, et al

    . Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion. Cardiovasc Diagn Ther 2014;4:147–64.

    PubMed
25. 25.↵
    1. Santos P,
    2. Peck KK,
    3. Arevalo-Perez J, et al

    . T1-weighted dynamic contrast-enhanced MR perfusion imaging characterizes tumor response to radiation therapy in chordoma. AJNR Am J Neuroradiol 2017;38:2210–16 doi:10.3174/ajnr.A5383 pmid:28912284

    Abstract/FREE Full Text
26. 26.↵
    1. Guan Y,
    2. Peck KK,
    3. Lyo J, et al

    . T1-weighted dynamic contrast-enhanced MRI to differentiate nonneoplastic and malignant vertebral body lesions in the spine. Radiology 2020;297:382–89 doi:10.1148/radiol.2020190553 pmid:32870135

    CrossRefPubMed
27. 27.↵
    1. Brix G,
    2. Semmler W,
    3. Port R, et al

    . Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621–28 doi:10.1097/00004728-199107000-00018 pmid:2061479

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Camelo F,
    2. Peck KK,
    3. Saha A, et al

    . Delay of aortic arterial input function time improves detection of malignant vertebral body lesions on dynamic contrast-enhanced MRI perfusion. Cancers (Basel) 2023;15:2353 doi:10.3390/cancers15082353

    CrossRefPubMed
29. 29.↵
    1. Liu Y-J,
    2. Huang G-S,
    3. Juan C-J, et al

    . Intervertebral disc degeneration related to reduced vertebral marrow perfusion at dynamic contrast-enhanced MRI. AJR Am J Roentgenol 2009;192:974–79 doi:10.2214/AJR.08.1597 pmid:19304703

    CrossRefPubMed
30. 30.↵
    1. Bilgen M,
    2. Abbe R,
    3. Narayana PA

    . Dynamic contrast-enhanced MRI of experimental spinal cord injury: in vivo serial studies. Magn Reson Med 2001;45:614–22 doi:10.1002/mrm.1083 pmid:11283989

    CrossRefPubMed
31. 31.↵
    1. Mauch JT,
    2. Carr CM,
    3. Cloft H, et al

    . Review of the imaging features of benign osteoporotic and malignant vertebral compression fractures. AJNR Am J Neuroradiol 2018;39:1584–92 doi:10.3174/ajnr.A5528 pmid:29348133

    Abstract/FREE Full Text
32. 32.↵
    1. Croarkin E

    . Osteopenia in the patient with cancer. Phys Ther 1999;79:196–201.doi:10.1093/ptj/79.2.196

    FREE Full Text
33. 33.↵
    1. Arevalo-Perez J,
    2. Peck KK,
    3. Lyo JK, et al

    . Differentiating benign from malignant vertebral fractures using T1-weighted dynamic contrast-enhanced MRI. J Magn Reson Imaging 2015;42:1039–47 doi:10.1002/jmri.24863 pmid:25656545

    CrossRefPubMed
34. 34.↵
    1. Saha A,
    2. Peck KK,
    3. Karimi S, et al

    . Dynamic contrast-enhanced MR perfusion: role in diagnosis and treatment follow-up in patients with vertebral body tumors. Neuroimaging Clin N Am 2023;33:477–86 doi:10.1016/j.nic.2023.03.006 pmid:37356863

    CrossRefPubMed
35. 35.↵
    1. Abul-Kasim K,
    2. Persson E,
    3. Levinsson A, et al

    . Vertebral hemangiomas: prevalence, new classification and natural history. Magnetic resonance imaging-based retrospective longitudinal study. Neuroradiol J 2023;36:23–30 doi:10.1177/19714009221098115 pmid:35507423

    CrossRefPubMed
36. 36.↵
    1. Morales KA,
    2. Arevalo-Perez J,
    3. Peck KK, et al

    . Differentiating atypical hemangiomas and metastatic vertebral lesions: the role of T1-weighted dynamic contrast-enhanced MRI. AJNR Am J Neuroradiol 2018;39:968–73 doi:10.3174/ajnr.A5630 pmid:29650780

    Abstract/FREE Full Text
37. 37.↵
    1. McEvoy SH,
    2. Farrell M,
    3. Brett F, et al

    . Haemangioma, an uncommon cause of an extradural or intradural extramedullary mass: case series with radiological pathological correlation. Insights Imaging 2016;7:87–98 doi:10.1007/s13244-015-0432-y pmid:26385689

    CrossRefPubMed
38. 38.↵
    1. Lang N,
    2. Su M-Y,
    3. Yu HJ, et al

    . Differentiation of myeloma and metastatic cancer in the spine using dynamic contrast-enhanced MRI. Magn Reson Imaging 2013;31:1285–91 doi:10.1016/j.mri.2012.10.006 pmid:23290477

    CrossRefPubMed
39. 39.↵
    1. Khadem NR,
    2. Karimi S,
    3. Peck KK, et al

    . Characterizing hypervascular and hypovascular metastases and normal bone marrow of the spine using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2012;33:2178–85 doi:10.3174/ajnr.A3104 pmid:22555585

    Abstract/FREE Full Text
40. 40.↵
    1. Meng X-X,
    2. Zhang Y-Q,
    3. Liao H-Q, et al

    . Dynamic contrast-enhanced MRI for the assessment of spinal tumor vascularity: correlation with angiography. Eur Spine J 2016;25:3952–61 doi:10.1007/s00586-016-4713-z pmid:27448809

    CrossRefPubMed
41. 41.↵
    1. Saha A,
    2. Peck KK,
    3. Lis E, et al

    . Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases: clinical utilities and implications. Spine (Phila Pa 1976) 2014;39:E1433–40 doi:10.1097/BRS.0000000000000570 pmid:25188594

    CrossRefPubMed
42. 42.↵
    1. Cuvinciuc V,
    2. Viallon M,
    3. Barnaure I, et al

    . Dynamic contrast-enhanced MR perfusion of intradural spinal lesions. AJNR Am J Neuroradiol 2017;38:192–94 doi:10.3174/ajnr.A4995 pmid:27856434

    Abstract/FREE Full Text
43. 43.↵
    1. Verma M,
    2. Sood S,
    3. Singh B, et al

    . Dynamic contrast-enhanced magnetic resonance perfusion volumetrics can differentiate tuberculosis of the spine and vertebral malignancy. Acta Radiology 2022;63:1504–12 doi:10.1177/02841851211043838 pmid:34806421

    CrossRefPubMed
44. 44.↵
    1. Chu S,
    2. Karimi S,
    3. Peck KK, et al

    . Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging: evaluation of tumor response to radiation therapy. Spine (Phila Pa 1976) 2013;38:E1418–24 doi:10.1097/BRS.0b013e3182a40838 pmid:23873238

    CrossRefPubMed
45. 45.↵
    1. Chen Y,
    2. Zhang E,
    3. Wang Q, et al

    . Use of dynamic contrast-enhanced MRI for the early assessment of outcome of CyberKnife stereotactic radiosurgery for patients with spinal metastases. Clin Radiology 2021;76:864.e1–e6 doi:10.1016/j.crad.2021.07.008 pmid:34404514

    CrossRefPubMed
46. 46.↵
    1. Lis E,
    2. Saha A,
    3. Peck KK, et al

    . Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy. Neurosurg Focus 2017;42:E9 doi:10.3171/2016.9.FOCUS16378 pmid:28041318

    CrossRefPubMed
47. 47.↵
    1. Kumar KA,
    2. Peck KK,
    3. Karimi S, et al

    . A pilot study evaluating the use of dynamic contrast-enhanced perfusion MRI to predict local recurrence after radiosurgery on spinal metastases. Technol Cancer Res Treat 2017;16:857–65 doi:10.1177/1533034617705715 pmid:28449626

    CrossRefPubMed
48. 48.↵
    1. Walcott BP,
    2. Nahed BV,
    3. Mohyeldin A, et al

    . Chordoma: current concepts, management, and future directions. Lancet Oncol 2012;13:e69–76 doi:10.1016/S1470-2045(11)70337-0 pmid:22300861

    CrossRefPubMedWeb of Science
49. 49.↵
    1. Tan CH,
    2. Hobbs BP,
    3. Wei W, et al

    . Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 2015;204:W439–48 doi:10.2214/AJR.14.13373 pmid:25794093

    CrossRefPubMed
50. 50.↵
    1. Zhang J,
    2. Chen Y,
    3. Zhang Y, et al

    . Diagnosis of spinal lesions using perfusion parameters measured by DCE-MRI and metabolism parameters measured by PET/CT. Eur Spine J 2020;29:1061–70 doi:10.1007/s00586-019-06213-9 pmid:31754820

    CrossRefPubMed